SEARCH
Search Details
Murata Daiki
Division of Respirology Neurology and Rheumatology Department of Internal Medicine
Assistant Professor
Career
■ Career
- Apr. 2025 - Present
Kindai University, Faculty of Medicine, Department of Medical Oncology - Apr. 2024 - Mar. 2025
Kurume University School of Medicine, Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine - Oct. 2022 - Mar. 2024
Saga-Ken Medical Centre Koseikan, Division of Respiratory Medicine - Apr. 2021 - Sep. 2022
Kurume University School of Medicine, Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine - Apr. 2019 - Mar. 2021
National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, junior resident
Research activity information
■ Award
- Jan. 2024
日本内科学会, 第344回日本内科学会九州地方会 指導医賞
肺ノカルジア症と肺非結核性抗酸菌症を合併した非免疫不全者の1例
村田大樹 - Nov. 2023
日本内科学会, 第343回日本内科学会九州地方会 内科専攻医賞
高齢COVID-19中等症Ⅱ患者における発症早期の血液検査所見からの死亡転帰の予測
村田大樹 - Feb. 2023
日本肺癌学会九州支部学術集会・日本呼吸器内視鏡学会, 優秀演題賞
悪液質が非小細胞肺癌に対する免疫療法の腫瘍縮小効果に及ぼす影響
村田大樹
- Soluble Immune Mediators Regulated by CD163+ Macrophages or CD8+ TILs According to EGFR Mutation Status During Anti-PD-1/L1 Monotherapy for NSCLC
Daiki Murata; Koichi Azuma; Kenta Murotani; Akihiko Kawahara; Tomoaki Hoshino
2026 - Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer
Ryo Yano; Takaaki Tokito; Kenta Murotani; Daiki Murata; Shingo Tsuneyoshi; Hidenobu Ishii; Koichi Azuma; Tomoaki Hoshino
BMC Cancer, 19 Dec. 2025, [Reviewed] - Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study
Daiki Murata; Koichi Azuma; Kenta Murotani; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Naoya Nishioka; Tadaaki Yamada; Koichi Takayama
Lung Cancer, Nov. 2025, [Reviewed]
Lead - Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
AOSA SASADA; HAYATO KAWACHI; TADAAKI YAMADA; TAE HATA; YASUHIRO GOTO; AKIHIKO AMANO; YOSHIKI NEGI; SATOSHI WATANABE; NAOKI FURUYA; TOMOHIRO OBA; TATSUKI IKOMA; AKIRA NAKAO; KEIKO TANIMURA; HIROKAZU TANIGUCHI; AKIHIRO YOSHIMURA; TOMOYA FUKUI; DAIKI MURATA; KYOICHI KAIRA; SHINSUKE SHIOTSU; ASUKA OKADA; YUSUKE CHIHARA; TAKASHI KIJIMA; KOICHI TAKAYAMA
Anticancer Research, 28 Oct. 2025 - Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab
Takaaki Tokito; Koichi Azuma; Kenta Murotani; Norikazu Matsuo; Goushi Matama; Daiki Murata; Tetsuro Sasada; Tomoaki Hoshino
Translational Lung Cancer Research, Oct. 2025, [Reviewed] - Dual Targets, Two Paths: Amivantamab: A Promising Treatment for NSCLC With Exon 14 Skipping Mutations of MET
Daiki Murata; Hidetoshi Hayashi
Journal of Thoracic Oncology, Sep. 2025
Lead - Exploration of plasma factor profiles involved in tumor growth factors in non-small cell carcinoma patients with interstitial pneumonia
Goushi Matama; Koichi Azuma; Akimasa Sekine; Norikazu Matsuo; Koji Okudela; Kenta Murotani; Akihiko Kawahara; Masaki Tominaga; Yoshiaki Zaizen; Daiki Murata; Tetsuro Sasada; Takashi Ogura
Respiratory Investigation, Sep. 2025, [Reviewed] - Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
Daiki Murata; Koichi Azuma; Kenta Murotani; Yoshiaki Zaizen; Tomoaki Hoshino
Cancer Immunology, Immunotherapy, 05 Jul. 2025, [Reviewed]
Lead - Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Tae Hata; Tadaaki Yamada; Yasuhiro Goto; Akihiko Amano; Yoshiki Negi; Satoshi Watanabe; Naoki Furuya; Tomohiro Oba; Tatsuki Ikoma; Akira Nakao; Keiko Tanimura; Hirokazu Taniguchi; Akihiro Yoshimura; Tomoya Fukui; Daiki Murata; Kyoichi Kaira; Shinsuke Shiotsu; Makoto Hibino; Asuka Okada; Yusuke Chihara; Hayato Kawachi; Takashi Kijima; Koichi Takayama
Cancer Research Communications, 01 Jul. 2025, [Reviewed] - SMARCA4-deficient Undifferentiated Thoracic Tumor That Responded to Pembrolizumab Monotherapy in a Patient with a Poor Performance Status
Daiki Murata; Koichi Azuma; Kenji Tsumura; Tomohiro Tanaka; Yoshihisa Tokunaga; Yoshiaki Zaizen; Tomoaki Hoshino
Haigan, 20 Jun. 2025, [Reviewed]
Lead - Hemophagocytic Lymphohistiocytosis Due to Ipilimumab plus Nivolumab in a Patient with Pleural Mesothelioma
Daiki Murata; Koichi Azuma; Kenji Tsumura; Tomohiro Tanaka; Hiroyoshi Yamada; Goushi Matama; Tomoaki Hoshino
Haigan, 20 Jun. 2025, [Reviewed]
Lead - Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression
Hayato Kawachi; Tae Hata; Tadaaki Yamada; Yasuhiro Goto; Akihiko Amano; Yoshiki Negi; Satoshi Watanabe; Naoki Furuya; Tomohiro Oba; Tatsuki Ikoma; Akira Nakao; Keiko Tanimura; Hirokazu Taniguchi; Akihiro Yoshimura; Tomoya Fukui; Daiki Murata; Kyoichi Kaira; Shinsuke Shiotsu; Makoto Hibino; Asuka Okada; Yusuke Chihara; Takashi Kijima; Koichi Takayama
Translational Lung Cancer Research, May 2025 - Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.
Shiho Goda; Tadaaki Yamada; Kenji Morimoto; Tae Hata; Yasuhiro Goto; Akihiko Amano; Yoshiki Negi; Satoshi Watanabe; Naoki Furuya; Tomohiro Oba; Tatsuki Ikoma; Akira Nakao; Keiko Tanimura; Hirokazu Taniguchi; Akihiro Yoshimura; Tomoya Fukui; Daiki Murata; Kyoichi Kaira; Shinsuke Shiotsu; Asuka Okada; Makoto Hibino; Yusuke Chihara; Takashi Kijima; Koichi Takayama
Translational lung cancer research, 30 Apr. 2025 - Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study
Naoya Nishioka; Tae Hata; Tadaaki Yamada; Yasuhiro Goto; Akihiko Amano; Yoshiki Negi; Satoshi Watanabe; Naoki Furuya; Tomohiro Oba; Tatsuki Ikoma; Akira Nakao; Keiko Tanimura; Hirokazu Taniguchi; Akihiro Yoshimura; Tomoya Fukui; Daiki Murata; Kyoichi Kaira; Shinsuke Shiotsu; Makoto Hibino; Asuka Okada; Yusuke Chihara; Hayato Kawachi; Takashi Kijima; Koichi Takayama
Cancer Research and Treatment, 15 Apr. 2025 - PD-L1低発現の高齢者進行期NSCLCに対する複合免疫療法の有効性
谷口 寛和; 河内 勇人; 畑 妙; 山田 忠明; 後藤 康洋; 天野 明彦; 木島 貴志; 渡部 聡; 古屋 直樹; 大場 智広; 生駒 龍興; 中尾 明; 谷村 恵子; 吉村 彰紘; 福井 朋也; 村田 大樹; 解良 恭一; 高山 浩一
日本呼吸器学会誌, Mar. 2025 - Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.
Tae Hata; Tadaaki Yamada; Yasuhiro Goto; Akihiko Amano; Yoshiki Negi; Satoshi Watanabe; Naoki Furuya; Tomohiro Oba; Tatsuki Ikoma; Akira Nakao; Keiko Tanimura; Hirokazu Taniguchi; Akihiro Yoshimura; Tomoya Fukui; Daiki Murata; Kyoichi Kaira; Shinsuke Shiotsu; Makoto Hibino; Asuka Okada; Yusuke Chihara; Hayato Kawachi; Takashi Kijima; Koichi Takayama
Lung cancer (Amsterdam, Netherlands), Feb. 2025 - The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer
Daiki Murata; Koichi Azuma; Yuuya Nishii; Kenta Murotani; Goushi Matama; Akihiko Kawahara; Takaaki Tokito; Tetsuro Sasada; Tomoaki Hoshino
Chemotherapy, 22 Jan. 2025 - Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.
Tae Hata; Tadaaki Yamada; Yasuhiro Goto; Akihiko Amano; Yoshiki Negi; Satoshi Watanabe; Naoki Furuya; Tomohiro Oba; Tatsuki Ikoma; Akira Nakao; Keiko Tanimura; Hirokazu Taniguchi; Akihiro Yoshimura; Tomoya Fukui; Daiki Murata; Kyoichi Kaira; Shinsuke Shiotsu; Makoto Hibino; Asuka Okada; Yusuke Chihara; Hayato Kawachi; Takashi Kijima; Koichi Takayama
Clinical lung cancer, 04 Jan. 2025 - Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy
Daiki Murata; Koichi Azuma; Kenta Murotani; Akihiko Kawahara; Yuuya Nishii; Takaaki Tokito; Tetsuro Sasada; Tomoaki Hoshino
Cancer Immunology, Immunotherapy, 05 Sep. 2024 - Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Daiki Murata; Koichi Azuma; Kenta Murotani; Norikazu Matsuo; Goushi Matama; Takaaki Tokito; Tetsuro Sasada; Tomoaki Hoshino
Lung cancer (Amsterdam, Netherlands), Oct. 2023 - Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
Daiki Murata; Koichi Azuma; Norikazu Matsuo; Kenta Murotani; Goushi Matama; Akihiko Kawahara; Tetsuro Sasada; Takaaki Tokito; Tomoaki Hoshino
Cancer Medicine, Oct. 2023 - Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Norikazu Matsuo; Koichi Azuma; Kenta Murotani; Daiki Murata; Goushi Matama; Akihiko Kawahara; Takashi Kojima; Takaaki Tokito; Tomoaki Hoshino
Thoracic cancer, May 2023 - A Rare Case of Diffuse Bilateral Minute Pulmonary Meningothelial-like Nodules Increasing over the Short Term and Resembling Metastatic Lung Cancer.
Daiki Murata; Yoshiaki Zaizen; Saeko Tokisawa; Goushi Matama; Tomonori Chikasue; Yuuya Nishii; Shuuhei Ohno; Kenji Tsumura; Masaki Tominaga; Junya Fukuoka; Kiminori Fujimoto; Tomoaki Hoshino
Internal medicine (Tokyo, Japan), 15 Apr. 2023 - Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer
Daiki Murata; Koichi Azuma; Goushi Matama; Yoshiaki Zaizen; Norikazu Matsuo; Kenta Murotani; Takaaki Tokito; Tomoaki Hoshino
Thoracic Cancer, Jan. 2023 - A case of cytokine release syndrome accompanied with COVID‐19 infection during treatment with immune checkpoint inhibitors for non‐small cell lung cancer
Daiki Murata; Koichi Azuma; Saeko Tokisawa; Takaaki Tokito; Tomoaki Hoshino
Thoracic Cancer, Oct. 2022 - Hematogenous metastasis to colon from gallbladder cancer.
Daiki Murata; Atsushi Yamaguchi; Yuzuru Tamaru; Ryusaku Kusunoki; Toshio Kuwai; Hirotaka Kouno; Akira Ishikawa; Kazuya Kuraoka; Hiroshi Kohno
JGH open : an open access journal of gastroenterology and hepatology, May 2021
- Efficacy of Chemotherapy with or without Immunotherapy in Elderly NSCLC Patients with Low PD-L1 Expression
谷口寛和; 河内勇人; 畑妙; 山田忠明; 後藤康洋; 天野明彦; 木島貴志; 渡部聡; 古屋直樹; 大場智広; 生駒龍興; 中尾明; 谷村恵子; 吉村彰紘; 福井朋也; 村田大樹; 解良恭一; 高山浩一
日本呼吸器学会誌(Web), 2025 - 悪液質を有する非小細胞肺癌患者において活性型および非活性型Ghrelinが免疫チェックポイント阻害剤単剤治療に及ぼす影響に関する検討
村田 大樹; 東 公一; 西井 裕哉; 時任 高章; 星野 友昭
肺癌, Jun. 2024 - 腫瘍 免疫療法・予後予測因子 Multiplex assayを用いた非小細胞肺癌に対する免疫チェックポイント阻害剤単剤治療における予後予測因子の探索的検討
村田 大樹; 東 公一; 西井 裕哉; 時任 高章; 星野 友昭
日本呼吸器学会誌, Mar. 2024 - 肺癌 合併症 間質性肺異常陰影が非小細胞肺癌患者に対する免疫チェックポイント阻害薬単剤治療に及ぼす影響に関する検討
村田 大樹; 東 公一; 西井 裕哉; 時任 高章; 星野 友昭
日本呼吸器学会誌, Mar. 2024 - PD-L1低発現進行非小細胞肺癌患者における重症免疫関連有害事象が臨床転帰へ与える影響
合田志穂; 山田忠明; 畑妙; 後藤康洋; 天野明彦; 木島貴志; 渡部聡; 古屋直樹; 大場智広; 生駒龍興; 中尾明; 谷村恵子; 谷口寛和; 吉村彰紘; 福井朋也; 村田大樹; 解良恭一; 塩津伸介; 岡田あすか; 高山浩一
日本肺癌学会学術集会号(CD-ROM), 2024 - PD-L1 1-49%進行非小細胞肺癌の初回治療における治験適格基準の意義
畑妙; 山田忠明; 後藤康洋; 天野明彦; 木島貴志; 渡部聡; 古屋直樹; 大場智広; 生駒龍興; 中尾明; 谷村恵子; 谷口寛和; 吉村彰紘; 福井朋也; 村田大樹; 解良恭一; 塩津伸介; 日比野真; 岡田あすか; 高山浩一
日本肺癌学会学術集会号(CD-ROM), 2024 - PD-L1低発現進行非小細胞肺がん複合免疫療法における抗菌薬投与歴の臨床的意義
畑妙; 山田忠明; 後藤康洋; 天野明彦; 木島貴志; 渡部聡; 古屋直樹; 大場智広; 生駒龍興; 中尾明; 谷村恵子; 谷口寛和; 吉村彰紘; 福井朋也; 村田大樹; 解良恭一; 塩津伸介; 日比野真; 岡田あすか; 高山浩一
日本肺癌学会学術集会号(CD-ROM), 2024 - 間質性肺炎を合併したPD-L1低発現進行非小細胞肺癌における免疫療法の臨床的意義:多施設共同観察研究
笹田碧沙; 山田忠明; 畑妙; 後藤康洋; 天野明彦; 木島貴志; 渡部聡; 古屋直樹; 大場智広; 生駒龍興; 中尾明; 谷村恵子; 谷口寛和; 吉村彰紘; 福井朋也; 村田大樹; 解良恭一; 塩津伸介; 岡田あすか; 高山浩一
日本肺癌学会学術集会号(CD-ROM), 2024 - PD-L1低発現進行非扁平上皮・非小細胞肺癌におけるICI併用化学療法のICIレジメン別検討
畑妙; 山田忠明; 後藤康洋; 天野明彦; 木島貴志; 渡部聡; 古屋直樹; 大場智広; 生駒龍興; 中尾明; 谷村恵子; 谷口寛和; 吉村彰紘; 福井朋也; 村田大樹; 解良恭一; 塩津伸介; 日比野真; 岡田あすか; 高山浩一
日本肺癌学会学術集会号(CD-ROM), 2024 - 非小細胞肺癌に対する抗PD-1抗体/抗CTLA-4抗体併用療法におけるHyperprogressive disease
村田 大樹; 松尾 規和; 大野 修平; 西井 裕哉; 津村 健二; 石井 秀宣; 時任 高章; 東 公一; 星野 友昭
日本呼吸器学会誌, Apr. 2022 - プラチナ製剤併用化学療法増悪後に複合免疫療法が奏効した進行胸腺小細胞癌の1例
村田 大樹; 松尾 規和; 石井 秀宣; 時任 高章; 東 公一; 星野 友昭
肺癌, Apr. 2022 - 気管支充填術と胸腔内洗浄により治癒した肺膿瘍穿破による有瘻性膿胸の1例
村田 大樹; 三村 剛史; 鍵本 篤志; 平川 哲; 三登 峰代; 福原 和秀; 妹尾 直; 中野 喜久雄; 山下 芳典
広島医学, Jul. 2021
- -
Daiki Murata; Koichi Azuma, Joint work, KRAS G12C変異陽性非小細胞肺癌に対する薬物療法
科学評論社, Jul. 2025 - The cutting edge of immune checkpoint therapy
Daiki Murata; Koichi Azuma, Joint work, 肺がん領域における最近のトピックス
株式会社 北隆館 / 株式会社 ニュー・サイエンス社, Apr. 2025 - 腫瘍内科32巻4号
村田大樹; 東公一, 免疫療法の光と影 抗CTLA-4抗体と抗PD-1抗体あるいは抗PD-L1抗体の併用の安全性と有効性のバランスは?
科学評論社, Oct. 2023 - 日本臨牀80巻増刊 最新臨床肺癌学-診断・治療の最新動向-
村田大樹; 東公一, V. 治療 集学的治療 脳転移の管理
日本臨牀, Dec. 2022
